Carol Delaney

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients

D. Neuberg, D. Kufe, D. DeAngelo, 2013 .

Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial.

S. Jagannath, N. Munshi, P. Richardson, 2006 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation

N. Munshi, J. Laubach, P. Richardson, 2012 .